Related Experiment Video
Updated: Aug 6, 2026
Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
[Modulation effect of lithium on IL-2 and IFNr production by human peripheral blood mononuclear cells]
1Cancer Institute, Chinese Academy of Medical Sciences, Beijing.
Insights
Lithium chloride enhances immune responses by increasing interleukin-2 (IL-2) and interferon-gamma (IFN-γ) production in peripheral blood mononuclear cells (PBMC). This immunomodulatory effect shows promise for clinical applications in cancer patients.
Area of Science:
- Immunology
- Pharmacology
Context:
- Investigates the immunomodulatory effects of lithium chloride.
- Assesses interleukin-2 (IL-2) and interferon-gamma (IFN-γ) production in peripheral blood mononuclear cells (PBMC).
- Compares immune cell function in normal subjects and cancer patients.
Purpose:
- To evaluate lithium chloride's potential as an immunoregulatory agent.
- To determine the effect of lithium on IL-2 and IFN-γ production in vitro.
- To assess the efficacy of lithium in patients with varying levels of these cytokines.
Summary:
- Lower IL-2 and IFN-γ levels were observed in lymphoma patients compared to normal subjects.
- Abnormal IFN-γ levels were noted in lung and esophageal cancer patients, while IL-2 levels remained normal.
- In vitro incubation with lithium chloride and recombinant IL-2 (rIL-2) upregulated IL-2 and IFN-γ production in both normal subjects and cancer patients.
- Lithium demonstrated a more potent effect than rIL-2 in increasing cytokine levels.
- Lithium effectively upregulated IFN-γ in patients with initially low levels.
Impact:
- Lithium chloride shows significant potential as a novel immunoregulatory agent for clinical use.
- The findings suggest lithium could be beneficial in managing immune deficiencies associated with certain cancers.
- Further research into lithium's immunomodulatory mechanisms could lead to new therapeutic strategies.
Abstract:
The immunomodulatory effect of lithium chloride was studied. The IL-2 and IFNr production by peripheral blood mononuclear cells(PBMC) were assayed in 52 normal subjects and 156 cancer patients. IL-2 and IFN-r levels in lymphoma patients were lower than in normal subjects. The IFNr level in the majority of patients with lung and esophageal cancers was abnormal but the IL-2 level was within the normal range. When lithium, IL-2 was incubated with PBMC in vitro, upregulation of IL-2 and IFNr production was observed in normal subjects and cancer patients. The IL-2 and IFNr levels were significantly increased by both lithium and rIL-2 but the effect of lithium was more potent. Lithium upregulated IFNr in 70% of patients with low levels whereas it did so in only 10-20% of patients with high levels. Therefore, lithium is a promising new immunoregulatory agent for clinical use.
